BU

BUKWANG PHARMACEUTICAL IND CO.,LTD

R&D pharma firm developing drugs for CNS disorders, oncology, and metabolic diseases.

003000 | KO

Overview

Corporate Details

ISIN(s):
KR7003000007
LEI:
Country:
South Korea
Address:
서울특별시 동작구 대방동1길 47, 서울특별시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Bukwang Pharmaceutical Co., Ltd. is an R&D-focused pharmaceutical company engaged in the development, manufacturing, and commercialization of therapeutic drugs. The company employs an 'open innovation' strategy, utilizing strategic investments, joint ventures, research collaborations, and acquisitions to expand its drug pipeline and enhance its global competitiveness. Its development pipeline targets a range of conditions, with a focus on central nervous system (CNS) disorders such as schizophrenia (Lurasidone) and Parkinson's disease (JM-010), as well as oncology (SOL-804 for prostate cancer), liver diseases, and metabolic disorders. Through continuous research and strategic partnerships, Bukwang aims to become a global pharmaceutical innovator.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-29 00:00
Related Party Transaction
대규모기업집단현황공시[분기별공시(개별회사용)]
Korean 10.5 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.6 MB
2025-08-14 00:00
Regulatory News Service
지급수단별ㆍ지급기간별지급금액및분쟁조정기구에관한사항
Korean 11.3 KB
2025-07-24 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 86.0 KB
2025-07-24 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.4 KB
2025-07-24 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.4 KB
2025-07-22 00:00
Earnings Release
연결재무제표기준영업(잠정)실적(공정공시)
Korean 20.8 KB
2025-07-21 00:00
Major Shareholding Notification
최대주주등소유주식변동신고서
Korean 21.2 KB
2025-07-16 00:00
Share Issue/Capital Change
증권발행실적보고서
Korean 196.6 KB
2025-07-16 00:00
Share Issue/Capital Change
유상증자또는주식관련사채등의발행결과(자율공시)
Korean 8.5 KB
2025-07-16 00:00
Report Publication Announcement
기업설명회(IR)개최(안내공시)
Korean 6.2 KB
2025-07-15 00:00
Share Issue/Capital Change
유상증자또는주식관련사채등의청약결과(자율공시)
Korean 11.3 KB
2025-07-15 00:00
Related Party Transaction
[기재정정]특수관계인의유상증자참여
Korean 12.3 KB
2025-07-10 00:00
Share Issue/Capital Change
유상증자또는주식관련사채등의청약결과(자율공시)
Korean 12.1 KB
2025-07-10 00:00
Related Party Transaction
[기재정정]특수관계인의유상증자참여
Korean 12.9 KB

Automate Your Workflow. Get a real-time feed of all BUKWANG PHARMACEUTICAL IND CO.,LTD filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for BUKWANG PHARMACEUTICAL IND CO.,LTD

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for BUKWANG PHARMACEUTICAL IND CO.,LTD via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Apellis Pharmaceuticals, Inc. Logo
Developing novel C3 therapies for diseases in ophthalmology, nephrology, and hematology.
United States of America
APLS
Apimeds Pharmaceuticals US, Inc. Logo
Biopharma developing non-narcotic bee venom therapies for osteoarthritis pain and inflammation.
United States of America
APUS
Apogee Therapeutics, Inc. Logo
Developing novel antibody biologics for immunological and inflammatory (I&I) diseases.
United States of America
APGE
Apollomics Inc. Logo
A clinical-stage biopharma developing targeted oncology therapies for hard-to-treat cancers.
United States of America
APLM
Apontis Pharma AG Logo
German pharma firm specializing in Single Pills for cardiovascular and chronic diseases.
Germany
APPH
Develops DNA tech for genetic medicine, molecular diagnostics, and supply chain security.
United States of America
APDN
Applied Therapeutics, Inc. Logo
Develops treatments for rare metabolic and central nervous system (CNS) disorders.
United States of America
APLT
Aprea Therapeutics, Inc. Logo
Developing precision cancer therapies targeting DNA Damage Response for solid tumors.
United States of America
APRE
AprilBio Co.,Ltd. Logo
Develops long-acting biologic drugs for autoimmune diseases and oncology using its SAFA™ platform.
South Korea
397030
Aprogen Biologics Inc. Logo
Develops and manufactures novel biologic drugs and biosimilars for the professional market.
South Korea
003060

Talk to a Data Expert

Have a question? We'll get back to you promptly.